- Home
- CHRS vs FLC Comparison
CHRS vs FLC Comparison
Compare CHRS & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FLC
- Stock Information
- Founded
- CHRS 2010
- FLC 2003
- Country
- CHRS United States
- FLC United States
- Employees
- CHRS N/A
- FLC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FLC Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- FLC Finance
- Exchange
- CHRS Nasdaq
- FLC Nasdaq
- Market Cap
- CHRS 191.3M
- FLC 176.2M
- IPO Year
- CHRS 2014
- FLC N/A
- Fundamental
- Price
- CHRS $1.24
- FLC $17.01
- Analyst Decision
- CHRS Strong Buy
- FLC
- Analyst Count
- CHRS 4
- FLC 0
- Target Price
- CHRS $5.38
- FLC N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- FLC 37.8K
- Earning Date
- CHRS 03-12-2025
- FLC 01-01-0001
- Dividend Yield
- CHRS N/A
- FLC 6.64%
- EPS Growth
- CHRS N/A
- FLC N/A
- EPS
- CHRS N/A
- FLC N/A
- Revenue
- CHRS $304,340,000.00
- FLC N/A
- Revenue This Year
- CHRS $2.47
- FLC N/A
- Revenue Next Year
- CHRS N/A
- FLC N/A
- P/E Ratio
- CHRS N/A
- FLC N/A
- Revenue Growth
- CHRS 44.19
- FLC N/A
- 52 Week Low
- CHRS $0.66
- FLC $12.62
- 52 Week High
- CHRS $2.87
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- FLC 58.36
- Support Level
- CHRS $1.38
- FLC $16.87
- Resistance Level
- CHRS $1.45
- FLC $17.08
- Average True Range (ATR)
- CHRS 0.13
- FLC 0.20
- MACD
- CHRS -0.04
- FLC 0.04
- Stochastic Oscillator
- CHRS 4.50
- FLC 88.71
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.